Abstract
LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have